AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31289885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29649992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast walking training
Number of subjects: 225
Study 29649992 — intervention group
Group type: EXPERIMENTAL
Intervention: Step activity monitoring program
Number of subjects: 225
Study 29649992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast walking training + step activity monitoring program
Number of subjects: 225
Study 27067521 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin (7.5 mg/m² weekly for 14 days), Paclitaxel (50 mg/m²), Carboplatin (2 mg/mL/min over 30 min) during chemoradiotherapy; followed by Endostatin (7.5 mg/m² for 14 days), Paclitaxel (150 mg/m²), Carboplatin (5 mg/mL/min every 3 weeks for 2 cycles) as consolidation treatment.
Number of subjects: 19
Study 27067521 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin treatment
Number of subjects: 19
Study 24500751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mismatch prevalence (10%)
Number of subjects: 0
Study 24500751 — intervention group
Group type: COMPARATOR
Intervention: High mismatch prevalence (50%)
Number of subjects: 0
Study 22420935 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation Program (R & R)
Number of subjects: 31
Study 22420935 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 19589602 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs plus supportive care
Number of subjects: 0
Study 19589602 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study 18024167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0
Study 18024167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16109248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory smoking cessation intervention sessions (5 sessions)
Number of subjects: 105
Study 16109248 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard smoking cessation information)
Number of subjects: 105
Study 16109248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory smoking cessation intervention
Number of subjects: 105
Study 12075743 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating treatment group (A) received docetaxel 100 mg/m2 on days 1 and 43, alternating with cisplatin 100 mg/m2 on day 22 and vinorelbine 30 mg/m2 on days 22, 29, and 36.
Number of subjects: 70
Study 12075743 — intervention group
Group type: COMPARATOR
Intervention: Control group (B) received cisplatin 80 mg/m2 on days 1, 22, and 43, and vinorelbine 30 mg/m2 once a week from day 1 to day 57.
Number of subjects: 70
Study 9935086 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycolic acid cream twice daily (n=25)
Number of subjects: 100
Study 9935086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream qHS and tretinoin 0.025% cream twice daily (n=25)
Number of subjects: 100
Study 9935086 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (n=50, control)
Number of subjects: 100
Study 8800850 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson double pad antishear device
Number of subjects: 10
Study 8800850 — intervention group
Group type: COMPARATOR
Intervention: Standard single pad device
Number of subjects: 10
Study 2144207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 264
Study 2144207 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 264
Study 30702948 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based cardiac rehabilitation
Number of subjects: 80
Study 30702948 — intervention group
Group type: COMPARATOR
Intervention: Control group (enhanced standard care)
Number of subjects: 80
Study 28558739 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MCT group; 60-80% HRR)
Number of subjects: 20
Study 28558739 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIT group; 4 x 4 min at 85-95% peak HRR)
Number of subjects: 20
Study 28558739 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MCT group)
Number of subjects: 20
Study 28558739 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIT group)
Number of subjects: 20
Study 28558739 — intervention group
Group type: COMPARATOR
Intervention: Comparison between MCT and HIT
Number of subjects: 20
Study 26598141 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBVAC (5×10^5 CFU)
Number of subjects: 36
Study 26598141 — intervention group
Group type: COMPARATOR
Intervention: BCG (5×10^5 CFU)
Number of subjects: 36
Study 26598141 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBVAC (5×10^4 CFU)
Number of subjects: 36
Study 26598141 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBVAC (5×10^3 CFU)
Number of subjects: 36
Study 26598141 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBVAC and BCG (whole blood stimulation)
Number of subjects: 36
Study 26598141 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBVAC and BCG (IGRA results)
Number of subjects: 36
Study 23567001 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily insulin lispro mix 75/25 (LM75/25)
Number of subjects: 2091
Study 23567001 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin glargine
Number of subjects: 2091
Study 22161918 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained cohort
Number of subjects: 33
Study 22161918 — intervention group
Group type: COMPARATOR
Intervention: Untrained cohort
Number of subjects: 33
Study 19172535 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg micronized progesterone vaginally three times per day starting in the afternoon of oocyte retrieval until the morning of embryo transfer, in addition to standard hCG luteal-phase support.
Number of subjects: 197
Study 19172535 — intervention group
Group type: COMPARATOR
Intervention: Standard hCG luteal-phase support only.
Number of subjects: 197
Study 17062301 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 375 mg
Number of subjects: 524
Study 17062301 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg
Number of subjects: 524
Study 17062301 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 1500 mg
Number of subjects: 524
Study 17062301 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3582 2250 mg
Number of subjects: 524
Study 17062301 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 524
Study 17062301 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 524
Study 17062301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 12920841 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 ropivacaine + 2 mg.L‐1 fentanyl (Group RF)
Number of subjects: 42
Study 12920841 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 2 mg.L‐1 fentanyl (Group BF)
Number of subjects: 42
Study 12920841 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled epidural analgesia with 1.2 g.L‐1 bupivacaine + 80 mg.L‐1 morphine (Group BM)
Number of subjects: 42
Study 12920841 — intervention group
Group type: EXPERIMENTAL
Intervention: General‐epidural anesthesia and patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group EM)
Number of subjects: 42
Study 12920841 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled intravenous analgesia with 0.5 g.L‐1 morphine (Group M)
Number of subjects: 42
Study 10941607 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support associated with pharmacological treatment (benzodiazepine, gamma‐hydroxybutyric acid)
Number of subjects: 0
Study 9246967 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 92
Study 9246967 — intervention group
Group type: COMPARATOR
Intervention: Traditional colposuspension
Number of subjects: 92
Study 9246967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 1531827 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 1531827 — intervention group
Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 0
Study 3839018 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol treatment (prostaglandin synthesis precursor)
Number of subjects: 30
Study 3839018 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 3839018 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 25)
Number of subjects: 30
Study 29705519 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist anakinra
Number of subjects: 16
Study 29705519 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 26259762 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational materials + patient navigation services
Number of subjects: 1905
Study 26259762 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials (control group)
Number of subjects: 1905
Study 24115469 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support from a specially trained nurse (INS)
Number of subjects: 168
Study 24115469 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support from a psychologist (IPS)
Number of subjects: 168
Study 24115469 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 168
Study 21988960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledermix(®)
Number of subjects: 22
Study 21988960 — intervention group
Group type: COMPARATOR
Intervention: Ultracal XS(®)
Number of subjects: 22
Study 21988960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 20218813 — intervention group
Group type: EXPERIMENTAL
Intervention: OAP protocol
Number of subjects: 119
Study 20218813 — intervention group
Group type: COMPARATOR
Intervention: COMP protocol
Number of subjects: 119
Study 18280941 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoosteotomy
Number of subjects: 13
Study 18280941 — intervention group
Group type: COMPARATOR
Intervention: Conventional harvesting
Number of subjects: 13
Study 16181747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin (PRI) 3 g daily for 7 to 10 days
Number of subjects: 399
Study 16181747 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (AMX) 3 g daily for 7 to 10 days
Number of subjects: 399
Study 16181747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin (PRI)
Number of subjects: 399
Study 16181747 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (AMX)
Number of subjects: 399
Study 16181747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin (PRI) and Amoxicillin (AMX)
Number of subjects: 399
Study 12097669 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4 micromol vitamin A plus 1.07 mmol iron [A + Fe]
Number of subjects: 27
Study 12097669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.07 mmol iron [Fe]
Number of subjects: 27
Study 12097669 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4 micromol vitamin A [A]
Number of subjects: 27
Study 12097669 — intervention group
Group type: COMPARATOR
Intervention: Placebo [Pl]
Number of subjects: 27
Study 10433531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronation and flexion (PF)
Number of subjects: 135
Study 10433531 — intervention group
Group type: COMPARATOR
Intervention: Supination and flexion (SF)
Number of subjects: 135
Study 7720443 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm stapled colonic pouch low rectal anastomosis
Number of subjects: 38
Study 7720443 — intervention group
Group type: COMPARATOR
Intervention: Stapled straight coloanal anastomosis
Number of subjects: 38
Study 2039996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlocalized cancer cases
Number of subjects: 103
Study 2039996 — intervention group
Group type: COMPARATOR
Intervention: Localized malignancies
Number of subjects: 103
Study 6457618 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 6457618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study 6457618 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 0
Study 30224345 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 40 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (A arm)
Number of subjects: 55
Study 30224345 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg triweekly for 2 weeks with bicalutamide 50 mg/day in 3-week cycles (B arm)
Number of subjects: 55
Study 30224345 — intervention group
Group type: COMPARATOR
Intervention: High-dose bicalutamide (historical control)
Number of subjects: 55
Study 30224345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) in A arm
Number of subjects: 55
Study 30224345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) in B arm
Number of subjects: 55
Study 30224345 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal A-arm grade 3 AEs
Number of subjects: 55
Study 27896644 — intervention group
Group type: EXPERIMENTAL
Intervention: El Sistema music program (treatment group)
Number of subjects: 2914
Study 27896644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music program)
Number of subjects: 2914
Study 26655003 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg/0.05 ml) 1 week before surgery
Number of subjects: 60
Study 26655003 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival normal saline (1.25 mg/0.05 ml) 1 week before surgery
Number of subjects: 60
Study 26655003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 23409862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention dining halls (multicomponent, point‐of‐selection marketing campaign)
Number of subjects: 458
Study 23409862 — intervention group
Group type: COMPARATOR
Intervention: Control dining halls
Number of subjects: 458
Study 20180042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation for 45 days
Number of subjects: 43
Study 20180042 — intervention group
Group type: COMPARATOR
Intervention: IVF group
Number of subjects: 43
Study 20180042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation
Number of subjects: 43
Study 20086314 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg calcium plus 800 IU vitamin D(3)/d (Ca+VD group)
Number of subjects: 62
Study 20086314 — intervention group
Group type: COMPARATOR
Intervention: 200 mg calcium/d (Ca group)
Number of subjects: 62
Study 16101342 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention with counselling and/or nicotine replacement therapy (NRT)
Number of subjects: 0
Study 16101342 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention
Number of subjects: 0
Study 12051574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g b.i.d. dosing of Nitazoxanide
Number of subjects: 16
Study 12051574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g b.i.d. dosing of Nitazoxanide
Number of subjects: 16
Study 12051574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10086859 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer applied 3 times daily for 4 weeks on one forearm
Number of subjects: 0
Study 10086859 — intervention group
Group type: COMPARATOR
Intervention: Control forearm (no moisturizer)
Number of subjects: 0
Study 7733057 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 16
Study 7733057 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 16
Study 2327750 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg once daily for 5 days
Number of subjects: 0
Study 2327750 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg twice daily for 5 days
Number of subjects: 0
Study 6989699 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 30
Study 6989699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31540574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabomotizole (10 mg thrice a day)
Number of subjects: 286
Study 31540574 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 286
Study 28762756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 24 IU Oxytocin
Number of subjects: 38
Study 28762756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24927031 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcanalicular diode laser dacryocystorhinostomy (TCL‐DCR)
Number of subjects: 42
Study 24927031 — intervention group
Group type: COMPARATOR
Intervention: Nonoperated side (control)
Number of subjects: 42
Study 23430709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 633
Study 23430709 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of patch and oral NRT
Number of subjects: 633
Study 23430709 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalator to deliver oral NRT
Number of subjects: 633
Study 23430709 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT consumption
Number of subjects: 633
Study 21336953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral jumps
Number of subjects: 10
Study 21336953 — intervention group
Group type: COMPARATOR
Intervention: Lateral landings
Number of subjects: 10
Study 19727679 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg D-amphetamine
Number of subjects: 159
Study 19727679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 18076801 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate controlled-released tablet
Number of subjects: 121
Study 18076801 — intervention group
Group type: COMPARATOR
Intervention: Morphine hydrochloride sustained-released tablet
Number of subjects: 121
Study 15200750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER)
Number of subjects: 47
Study 15200750 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone controlled release (CR)
Number of subjects: 47
Study 15200750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 11425818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stimulation IVF (LS-IVF)
Number of subjects: 283
Study 11425818 — intervention group
Group type: COMPARATOR
Intervention: Standard IVF (S-IVF)
Number of subjects: 283
Study 9795874 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefits of screening presented as relative risk reduction
Number of subjects: 0
Study 9795874 — intervention group
Group type: COMPARATOR
Intervention: Benefits of screening presented as numbers needed to screen to save a life
Number of subjects: 0
Study 7516641 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 100
Study 7516641 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 100
Study 7516641 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin + G‐CSF
Number of subjects: 100
Study 7516641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2556079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (1 mg/kg)
Number of subjects: 12
Study 2556079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (2 mg/kg)
Number of subjects: 12
Study 2556079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin and Amikacin (500 mg)
Number of subjects: 12
Study 2556079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (1 or 2 mg/kg)
Number of subjects: 12
Study 2556079 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (500 mg)
Number of subjects: 12
Study 2556079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin and Amikacin combination
Number of subjects: 12
Study 4154124 — intervention group
Group type: EXPERIMENTAL
Intervention: S.A.I.M.R. antivenom (average dose 15.2 ml)
Number of subjects: 46
Study 4154124 — intervention group
Group type: COMPARATOR
Intervention: Behringwerke antivenom (average dose 37.9 ml)
Number of subjects: 46
Study 31230602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 32
Study 29069224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 16
Study 29069224 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 16
Study 26142347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysteropexy (LH)
Number of subjects: 132
Study 26142347 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 132
Study 23276410 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 63
Study 23276410 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 63
Study 23276410 — intervention group
Group type: COMPARATOR
Intervention: PRGF and Conventional surgery
Number of subjects: 63
Study 21563035 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 microgram every second hour, total 1600 microgram)
Number of subjects: 20
Study 21563035 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects with no previous use of beta2‐agonists)
Number of subjects: 20
Study 21563035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (asthmatics and controls)
Number of subjects: 20
Study 18487567 — intervention group
Group type: EXPERIMENTAL
Intervention: Local IHC
Number of subjects: 776
Study 18487567 — intervention group
Group type: EXPERIMENTAL
Intervention: Central IHC
Number of subjects: 776
Study 18487567 — intervention group
Group type: EXPERIMENTAL
Intervention: Central IHC Allred score
Number of subjects: 776
Study 15925911 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg orally daily
Number of subjects: 40
Study 15925911 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone 400 ug local sprays daily
Number of subjects: 40
Study 11668230 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP with dissection balloon
Number of subjects: 44